On June 10, 2026, the FDA updated the OTC label for alli (orlistat 60 mg) with rare warnings about acute kidney injury and kidney stones. Patients taking prescription orlistat (Xenical) can use the same symptom checklist—but should confirm suitability with their clinician.
If school officials report a possible measles exposure and your child may not have proof of immunity, act fast. CDC guidance includes MMR within 72 hours (for eligible people) and immune globulin within 6 days (for certain vulnerable groups). Measles symptoms usually start 7–14 days later—so know the warning signs.
The FDA issued a Class I correction notice for Automated Impella Controllers, focused on updated use instructions. Here’s what families should ask the care team and when to escalate for emergencies.
Starting April 1, 2026, CMS escalates enforcement of hospital price transparency requirements. If you’re uninsured or self-pay, CMS explains how the No Surprises Act good faith estimate process can help you plan—and how to dispute certain bills.
FDA and CDC are investigating a Cyclospora outbreak linked to shredded iceberg lettuce served at Taco Bell locations in Indiana, Kentucky, Michigan, Ohio, and West Virginia. If you ate the lettuce and develop diarrhea (especially within the prior two weeks), contact a clinician. Discard recalled iceberg lettuce and follow cleaning steps.
Starting July 31, 2026, CMS’s interim final rule creates a monthly “community engagement” requirement for some non-pregnant adults on Medicaid. If coverage verification is delayed or compliance/exemptions aren’t confirmed, families may face disrupted appointment planning—at a time when preventive care, including vaccines, matters. Here’s what’s known, what’s uncertain, and what caregivers can do now.
On June 12, 2026, the FDA cleared the first over-the-counter continuous glucose monitor (CGM) for children age 2+ who do not use insulin. Here’s what the device can do, the key safety limits FDA emphasized, and practical steps for families to use glucose data responsibly.
A new UK randomized trial found that adults with long COVID–related brain fog who received 10 telehealth sessions of goal-focused cognitive rehabilitation reported better day-to-day functional goal attainment at 3 months—an improvement that remained at 6 months. Here’s what the program involved, what seemed to improve most, and how U.S. readers can use CDC guidance to decide next steps.
CMS’ updated Hospital Price Transparency requirements for 2026 begin on Jan. 1, 2026, with enforcement of those updates starting Apr. 1, 2026. Rural patients can use the posted “shoppable services” display and the new median/percentile allowed-amount data to plan questions for insurers and hospitals—without expecting a perfect cost match.
Wisconsin extended BadgerCare Plus postpartum coverage from 60 days to up to about 12 months for many full-benefit members, effective in 2026. Because the state uses an “end of the month” rule, your exact coverage end date matters—especially for follow-up care, mental health support, and treating complications that can arise months after delivery.
On July 14, 2026, the FDA updated a Class I correction for Baxter Volara System single-patient-use circuits. The concern: possible air and medication leakage from the nebulizer cup when the cup isn’t properly locked after medication is added. Here’s how to check if your circuits are affected, what to do before each home therapy session, and when to get urgent help.
If a school or child care notice says there may have been measles exposure, timing and your child’s documented MMR doses matter. CDC guidance focuses on urgent, time-limited post-exposure options—often an MMR within 72 hours, or immune globulin for certain higher-risk people within 6 days.
New federal rules take effect June 8, 2026, and schools can expand fluid milk options again. Here’s what changes for families—plus a checklist for requesting lactose-free or a nutritionally equivalent nondairy substitute.
An NIH-highlighted Cell study suggests that, in some people with long COVID, the immune system may react to nervous-system-related targets—pointing to possible biologic subgroups. But CDC guidance remains clear: in the U.S., long COVID is diagnosed clinically, and there is still no definitive lab test for routine use.
Starting April 1, 2026, CMS enforcement begins for updated Hospital Price Transparency requirements tied to the CY 2026 machine-readable file. Here’s what changed for hospitals’ data (allowed amounts percentiles, attestation updates, and Type 2 NPI encoding) and what that does—and doesn’t—mean for patients’ bills.
If your bottle shows Lot 5950 with a best-by/expiration date of 02/2028, stop using it. FDA linked this lot to potential Aspergillus contamination and recalled it. People with weakened immune systems or certain lung diseases should be especially alert for concerning symptoms and seek medical care promptly if they develop them.
CDC’s “Activity Levels” turn community respiratory-virus surveillance into five labels (Very Low → Very High). Here’s how to interpret the signals—wastewater, emergency department/ARI activity, and severe-illness context—and what families, schools, and workplaces can do next without panic.
If your family used Nara Organics Whole Milk Organic Powdered Infant Formula, the FDA says stop using it now. Know the warning signs of infant botulism, preserve lot/use-by info, and get emergency care right away if symptoms appear.
If you may have been exposed to Andes virus through the 2026 U.S. cruise-ship outbreak and you develop fever or breathing symptoms, contact a clinician and public health promptly. CDC and WHO interim guidance explains the monitoring window after exposure, common symptom patterns, and how labs use coordinated testing—when different tests are most useful.
On July 1, 2026, the FDA expanded Casgevy (exagamglogene autotemcel) so some children age 2 and older with sickle cell disease (SCD) can be evaluated for the gene-edited, stem-cell therapy—previously approved for older children. Here’s what the FDA change does and does not mean, what benefits were seen in pediatric data, and what risks and long-term monitoring families should discuss.
CMS’s June 2026 Hospital Price Transparency FAQs update what hospitals must post online (including machine-readable expectations) and how consumers can use CMS’s enforcement-actions page. Here’s how to interpret what you find—and why those posted “prices/charges” may still not equal what you’ll personally pay with insurance.
On June 10, 2026, the FDA approved label updates for OTC alli (orlistat) 60 mg that add clearer warnings about rare but serious kidney risks, including kidney stones. If you have a history of kidney disease or kidney stones, the label advises asking a health care provider before using alli—and stopping alli and seeking medical guidance promptly if symptoms appear.
End of content
End of content
